Expansion of CpG methylation in the SFRP2 promoter region during colorectal tumorigenesis

Masanori Takeda, Takeshi Nagasaka, Sun Dong-Sheng, Hiroyuki Nishie, Tetsuhiro Oka, Eiji Yamada, Yoshiko Mori, Kunitoshi Shigeyasu, Tatsuya Morikawa, Satoshi Mizobuchi, Toshiyoshi Fujiwara

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Secreted frizsled-related protein 2, (SFRP2) is a Wnt inhibitor whose promoter CpGs were recently found to be methylated at high frequency in colorectal cancers (CRCs). We hypothesized that the pattern of SFRP2 methylation may differ throughout the promoter during progressive tumorigenesis. Using combined bisulfite restriction analysis (COBRA), two methylation-sensitive regions (Regions A and B) of the SFRP2 promoter were investigated in 569 specimens of colorectal tissue: 222 CRCs, 103 adenomatous polyps (APs), 208 normal colonic mucosa from CRC patients (N-Cs), and 36 normal colonic mucosa from subjects with no evidence of colorectal neoplasia at colonoscopy (N-Ns). Extensive (including both Regions A and B) and partial (either Region A or B) SFRP2 methylation levels were found in 61.7% and 24.8% of CRCs, 8.7% and 37.9% of APs, 3.9% and 39.9% of N-Cs, and 0% and 30.6% of N-Ns, respectively. Extensive methylation of the SFRP2 promoter was present primarily in CRCs, while partial methylation was common in APs. Whereas APs with the KRAS mutant showed no correlation to any pattern of SFRP2 methylation, extensive methylation of the SFRP2 promoter was significantly associated with KRAS mutant CRCs (p <.0001), suggesting that genetic alteration in the RAS-RAF pathway might precede the spread of CpG methylation through the SFRP2 promoter, which is observed in over 60% of advanced colorectal tumors.

Original languageEnglish
Pages (from-to)169-177
Number of pages9
JournalActa Medica Okayama
Volume65
Issue number3
Publication statusPublished - Jun 2011

Fingerprint

Methylation
Genetic Promoter Regions
Carcinogenesis
Colorectal Neoplasms
Adenomatous Polyps
Proteins
Mucous Membrane
Colonoscopy
Tumors
Tissue

Keywords

  • BRAF/KRAS mutations
  • Colorectal cancer
  • Promoter methylation

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Takeda, M., Nagasaka, T., Dong-Sheng, S., Nishie, H., Oka, T., Yamada, E., ... Fujiwara, T. (2011). Expansion of CpG methylation in the SFRP2 promoter region during colorectal tumorigenesis. Acta Medica Okayama, 65(3), 169-177.

Expansion of CpG methylation in the SFRP2 promoter region during colorectal tumorigenesis. / Takeda, Masanori; Nagasaka, Takeshi; Dong-Sheng, Sun; Nishie, Hiroyuki; Oka, Tetsuhiro; Yamada, Eiji; Mori, Yoshiko; Shigeyasu, Kunitoshi; Morikawa, Tatsuya; Mizobuchi, Satoshi; Fujiwara, Toshiyoshi.

In: Acta Medica Okayama, Vol. 65, No. 3, 06.2011, p. 169-177.

Research output: Contribution to journalArticle

Takeda, M, Nagasaka, T, Dong-Sheng, S, Nishie, H, Oka, T, Yamada, E, Mori, Y, Shigeyasu, K, Morikawa, T, Mizobuchi, S & Fujiwara, T 2011, 'Expansion of CpG methylation in the SFRP2 promoter region during colorectal tumorigenesis', Acta Medica Okayama, vol. 65, no. 3, pp. 169-177.
Takeda M, Nagasaka T, Dong-Sheng S, Nishie H, Oka T, Yamada E et al. Expansion of CpG methylation in the SFRP2 promoter region during colorectal tumorigenesis. Acta Medica Okayama. 2011 Jun;65(3):169-177.
Takeda, Masanori ; Nagasaka, Takeshi ; Dong-Sheng, Sun ; Nishie, Hiroyuki ; Oka, Tetsuhiro ; Yamada, Eiji ; Mori, Yoshiko ; Shigeyasu, Kunitoshi ; Morikawa, Tatsuya ; Mizobuchi, Satoshi ; Fujiwara, Toshiyoshi. / Expansion of CpG methylation in the SFRP2 promoter region during colorectal tumorigenesis. In: Acta Medica Okayama. 2011 ; Vol. 65, No. 3. pp. 169-177.
@article{050db488f1ea4654961ecd7faf456a10,
title = "Expansion of CpG methylation in the SFRP2 promoter region during colorectal tumorigenesis",
abstract = "Secreted frizsled-related protein 2, (SFRP2) is a Wnt inhibitor whose promoter CpGs were recently found to be methylated at high frequency in colorectal cancers (CRCs). We hypothesized that the pattern of SFRP2 methylation may differ throughout the promoter during progressive tumorigenesis. Using combined bisulfite restriction analysis (COBRA), two methylation-sensitive regions (Regions A and B) of the SFRP2 promoter were investigated in 569 specimens of colorectal tissue: 222 CRCs, 103 adenomatous polyps (APs), 208 normal colonic mucosa from CRC patients (N-Cs), and 36 normal colonic mucosa from subjects with no evidence of colorectal neoplasia at colonoscopy (N-Ns). Extensive (including both Regions A and B) and partial (either Region A or B) SFRP2 methylation levels were found in 61.7{\%} and 24.8{\%} of CRCs, 8.7{\%} and 37.9{\%} of APs, 3.9{\%} and 39.9{\%} of N-Cs, and 0{\%} and 30.6{\%} of N-Ns, respectively. Extensive methylation of the SFRP2 promoter was present primarily in CRCs, while partial methylation was common in APs. Whereas APs with the KRAS mutant showed no correlation to any pattern of SFRP2 methylation, extensive methylation of the SFRP2 promoter was significantly associated with KRAS mutant CRCs (p <.0001), suggesting that genetic alteration in the RAS-RAF pathway might precede the spread of CpG methylation through the SFRP2 promoter, which is observed in over 60{\%} of advanced colorectal tumors.",
keywords = "BRAF/KRAS mutations, Colorectal cancer, Promoter methylation",
author = "Masanori Takeda and Takeshi Nagasaka and Sun Dong-Sheng and Hiroyuki Nishie and Tetsuhiro Oka and Eiji Yamada and Yoshiko Mori and Kunitoshi Shigeyasu and Tatsuya Morikawa and Satoshi Mizobuchi and Toshiyoshi Fujiwara",
year = "2011",
month = "6",
language = "English",
volume = "65",
pages = "169--177",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "3",

}

TY - JOUR

T1 - Expansion of CpG methylation in the SFRP2 promoter region during colorectal tumorigenesis

AU - Takeda, Masanori

AU - Nagasaka, Takeshi

AU - Dong-Sheng, Sun

AU - Nishie, Hiroyuki

AU - Oka, Tetsuhiro

AU - Yamada, Eiji

AU - Mori, Yoshiko

AU - Shigeyasu, Kunitoshi

AU - Morikawa, Tatsuya

AU - Mizobuchi, Satoshi

AU - Fujiwara, Toshiyoshi

PY - 2011/6

Y1 - 2011/6

N2 - Secreted frizsled-related protein 2, (SFRP2) is a Wnt inhibitor whose promoter CpGs were recently found to be methylated at high frequency in colorectal cancers (CRCs). We hypothesized that the pattern of SFRP2 methylation may differ throughout the promoter during progressive tumorigenesis. Using combined bisulfite restriction analysis (COBRA), two methylation-sensitive regions (Regions A and B) of the SFRP2 promoter were investigated in 569 specimens of colorectal tissue: 222 CRCs, 103 adenomatous polyps (APs), 208 normal colonic mucosa from CRC patients (N-Cs), and 36 normal colonic mucosa from subjects with no evidence of colorectal neoplasia at colonoscopy (N-Ns). Extensive (including both Regions A and B) and partial (either Region A or B) SFRP2 methylation levels were found in 61.7% and 24.8% of CRCs, 8.7% and 37.9% of APs, 3.9% and 39.9% of N-Cs, and 0% and 30.6% of N-Ns, respectively. Extensive methylation of the SFRP2 promoter was present primarily in CRCs, while partial methylation was common in APs. Whereas APs with the KRAS mutant showed no correlation to any pattern of SFRP2 methylation, extensive methylation of the SFRP2 promoter was significantly associated with KRAS mutant CRCs (p <.0001), suggesting that genetic alteration in the RAS-RAF pathway might precede the spread of CpG methylation through the SFRP2 promoter, which is observed in over 60% of advanced colorectal tumors.

AB - Secreted frizsled-related protein 2, (SFRP2) is a Wnt inhibitor whose promoter CpGs were recently found to be methylated at high frequency in colorectal cancers (CRCs). We hypothesized that the pattern of SFRP2 methylation may differ throughout the promoter during progressive tumorigenesis. Using combined bisulfite restriction analysis (COBRA), two methylation-sensitive regions (Regions A and B) of the SFRP2 promoter were investigated in 569 specimens of colorectal tissue: 222 CRCs, 103 adenomatous polyps (APs), 208 normal colonic mucosa from CRC patients (N-Cs), and 36 normal colonic mucosa from subjects with no evidence of colorectal neoplasia at colonoscopy (N-Ns). Extensive (including both Regions A and B) and partial (either Region A or B) SFRP2 methylation levels were found in 61.7% and 24.8% of CRCs, 8.7% and 37.9% of APs, 3.9% and 39.9% of N-Cs, and 0% and 30.6% of N-Ns, respectively. Extensive methylation of the SFRP2 promoter was present primarily in CRCs, while partial methylation was common in APs. Whereas APs with the KRAS mutant showed no correlation to any pattern of SFRP2 methylation, extensive methylation of the SFRP2 promoter was significantly associated with KRAS mutant CRCs (p <.0001), suggesting that genetic alteration in the RAS-RAF pathway might precede the spread of CpG methylation through the SFRP2 promoter, which is observed in over 60% of advanced colorectal tumors.

KW - BRAF/KRAS mutations

KW - Colorectal cancer

KW - Promoter methylation

UR - http://www.scopus.com/inward/record.url?scp=79960142814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960142814&partnerID=8YFLogxK

M3 - Article

VL - 65

SP - 169

EP - 177

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 3

ER -